HealthSpan Partners, an affiliate of nonprofit hospital system Bon Secours Mercy Health, has raised its takeover bid for Surgery Partners (NASDAQ: SGRY) to up to $6 billion, successfully countering an unsolicited rival offer and sending Surgery Partners shares surging 12%.
📌 Deal Terms & Price Structure:
• $25.00/Share Base Cash Offer: HealthSpan lifted its cash offer from $23.50 to $25.00 per share for all public stockholders (excluding Bain Capital affiliates).
• Ticking Fee Upside to $26.61: If the merger receives shareholder approval but closes after March 1, 2027, shareholders will receive monthly accrual payments—potentially reaching $26.61 per share (an additional $1.61/share) if closing extends to the outside date of October 23, 2027.
• Bain Capital Backing: Key sponsor Bain Capital, which has held an anchor position since 2017 and currently owns 39% of Surgery Partners, has formally committed to back the revised HealthSpan agreement.
📌 Fending Off the $28 Unsolicited Bid:
• Higher Price Rejected Over Execution Risk: Surgery Partners’ board evaluated an unsolicited competing cash bid of $28.00 per share submitted on November 3.
• Regulatory Certainty Over Price: The independent special committee ultimately chose HealthSpan’s sweetened proposal, citing severe regulatory obstacles, extended timeline risks, and a lack of downside closing protections in the third-party bid.
• Expected Close: The transaction is slated to complete in Q1 2027.
📌 Strategic Scale & Healthcare Consolidation:
• National Outpatient Footprint: The combination significantly expands Bon Secours beyond its base of >45 acute-care hospitals, absorbing Surgery Partners’ nationwide network of over 200 surgical facilities across 30 states and approximately 5,000 affiliated physicians.
💡 Market Takeaway: In complex healthcare M&A, regulatory certainty and deal structure consistently trump headline valuation. Surgery Partners opted for high closing certainty and ticking-fee downside protection over a higher, antitrust-vulnerable counter-bid—demonstrating prudent board discipline in an evolving regulatory climate.